The efficacy of liraglutide on weight management was subsequently surpassed by semaglutide, which, when administered weekly at a dose of 2.4 mg in obese patients without diabetes, resulted in a weight reduction of 12.4% compared to placebo in the STEP 1 study [46], and a reduction of 9.4% compared to liraglutide 3.0 mg in the STEP-8 study [47]
GLP-1 RA glucagon-like peptide 1 receptor agonists, CI confidence interval, MACE major adverse cardiovascular event, MI myocardial infarction, SBP systolic blood pressure in mmHg, HR hazard ratio, RR relative risk, HF heart failure, LVEF left-ventricular ejection fraction a Primary or secondary outcome of interest as reported by the study Statistically significant confidence interval Major Adverse Cardiac Events Among Patients with T2DM Strong evidence supports using GLP-1 RAs to reduce MACE among patients with T2DM and established CVD
Ambient temperatures typically stay within the safe range, gel packs last longer, and the risk of both freezing and overheating is minimal
GLP-1 users are upping their spending on groceries and clothing
